Anuh Pharma Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: ANUHPHR BSE: 506260
₹87.40
▼ -2.28 (-2.54%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
72/100
Strong
Valuation
65/100
Fairly Valued
Momentum
50/100
Neutral

QVM read Quality business Quality Strong, Valuation Fairly Valued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹876 Cr
PE (TTM)
19.8
Industry median 36.1 (152 companies)
Price to Book
2.5
PEG (TTM)
-0.4
Institutions holding %
0.01%
FII + DII, latest filed period
Piotroski Score
4
Relative return vs Nifty50, qtr %
14.4
Relative return vs Sector, qtr %
9.1
Free Cash Flow
₹-11 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-31.33%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-11.60%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
9.70%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
37.63%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
3.93%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
2.22
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.00
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
228.59
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
5.89%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
8.74%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
7.76%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
7.50%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
15.43%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
11.87%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

3 of 7 met
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • Yes Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 4)
  • Yes Debt to equity is below 0.5 (0.00)
  • No Return on equity is 15% or more (11.9%)
  • No Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 3 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

2 of 3 met
  • Yes 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

1 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Sell Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-2.5%
Low 87.0000 · High 91.0500
1W return
-6.4%
Low 87.0000 · High 93.6000
1M return
6.5%
Low 78.1000 · High 99.5000
52W return
4.9%
Low 67.0000 · High 99.5000
Lifetime High ₹231.0200 (Jan. 1, 2025)
Lifetime Low ₹67.0000 (March 30, 2026)

Full price history and technicals →

EMA & SMA

Bullish3
Bearish3
5D
89.5
10D
90.2
20D
89.1
50D
85.3
100D
82.5
200D
79.3

Delivery and volume

Day avg. delivery
55.5%
Week avg. delivery
55.4%
Month avg. delivery
46.9%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

88.48
Pivot
First resistance89.97
Second resistance92.53
Third resistance94.02
First support85.92
Second support84.43
Third support81.87
Day RSI48.6
Day MFI39.1
Day MACD1.99
Day MACD signal2.85

Beta

1M0.63
3M0.19
1Y0.65
3Y0.81

Price change analysis

↑ 6.5%
Over 1 Month
LowHigh
78.1099.50
↑ 9.1%
Over 3 Months
LowHigh
75.4099.50
↑ 19.8%
Over 6 Months
LowHigh
70.8199.50
↑ 4.9%
Over 1 Year
LowHigh
67.0099.50
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 19.8 (own history: 12.0–23.4)
Sell Zone
Revenue (June 30, 2026)
₹194 Cr
Net profit (June 30, 2026)
₹11 Cr
Basic EPS (June 30, 2026)
₹1.1400

Ranks #94 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter71.80%
  • FII/FPI0.01%
  • Public28.19%

Largest holders

NameCategoryShares %Shares
BHARTI BIPIN SHAHPromoter19.4300%19474800
PRAFULLA LALIT SHAHPromoter14.4700%14499132
BIPIN NEMCHAND SHAHPromoter6.2100%6221720
BHARAT NEMCHAND SHAHPromoter3.7300%3734214
GAURAV SATISH SHAHPromoter3.1900%3200688

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 71.80% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings decreased from 0.05% to 0.01% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings were unchanged at 0.00% in Jun 2026 qtr

All shareholding details →

DateClientDealActionQuantityPriceExchange
29 Sep 2020 KETAN LALIT SHAH Bulk Sell 145,700 196.6200 BSE
7 May 2015 LALIT POPATLAL SHAH Bulk Buy 69,404 676.2800 BSE
7 May 2015 KETAN LALIT SHAH Bulk Buy 76,900 675.0300 BSE
7 May 2015 L P SHAH HOLDINGS AND TRADES LLP Bulk Sell 184,804 675.0200 BSE
20 Aug 2010 BHARAT NEMCHAND SHAH Bulk Sell 16,000 559.7500 BSE
20 Aug 2010 MRUDULA JAYANTILAL SHAH Bulk Buy 16,000 559.7500 BSE
16 Nov 2009 SAMIR JAYANTILAL SHAH Bulk Buy 15,856 322.5000 BSE
15 Sep 2008 L P SHAH HOLDING TRADES PVT LTD Bulk Buy 27,000 232.9000 BSE
15 Sep 2008 PRAFULLA LALITKUMAR SHAH Bulk Sell 27,000 232.9000 BSE
22 Feb 2008 LALIT P. SHAH Bulk Sell 80,000 240.5100 BSE

All bulk and block deals →

Last 12 months ₹1.50 per share
Dividend yield 1.72%
Ex-dateSubjectPer share (₹)Record date
5 Aug 2026 Dividend - Rs 1.50 Per Share 1.5000 5 Aug 2026
14 Aug 2025 Dividend - Rs 1.50 Per Share 1.5000 15 Aug 2025

Corporate Actions

Full history (3 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
15 Jul 2025BONUSBonus 1:1

All corporate actions →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
7 Aug 2026 Financial Results/Other business matters Yes
20 May 2026 Financial Results/Dividend/Other business matters Yes
6 Feb 2026 Financial Results/Other business matters Yes
7 Nov 2025 Financial Results/Other business matters Yes
8 Aug 2025 Financial Results/Other business matters Yes

Corporate Announcements

All 125 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
28 Sep 2026 Insider Trading / SAST Anuh Pharma Ltd - 506260 - Closure of Trading Window
28 Sep 2026 Trading Window Anuh Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
18 Sep 2026 Company Update Anuh Pharma Ltd - 506260 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (''''SEBI LODR'''')
18 Sep 2026 Action(s) taken or orders passed Anuh Pharma Limited has informed the Exchange about orders passed regarding receipt of Demand Order under Section 156 of the Income Tax Act, 1961.
19 Aug 2026 Investor Presentation Anuh Pharma Limited has informed the Exchange about Investor Presentation
14 Aug 2026 Change in Management Anuh Pharma Limited has informed the Exchange about change in Management
14 Aug 2026 Appointment Anuh Pharma Limited has informed the Exchange regarding Appointment of Mr Bipin N. Shah, Mr. Arun L. Todarwal and Mr. Ankit Chande as Directors of the company.
14 Aug 2026 General Updates Anuh Pharma Limited has informed the Exchange about General Updates under Regulation 30.
14 Aug 2026 Shareholders meeting Anuh Pharma Limited has submitted the Exchange a copy Voting Results and Scrutinizers report of Annual General Meeting held on August 12, 2026.
12 Aug 2026 Shareholders meeting Anuh Pharma Limited has informed the Exchange regarding Proceedings of 66th Annual General Meeting held on August 12, 2026

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.00)
  • Comfortable interest coverage (228.6x)
  • Healthy liquidity (Current Ratio 2.22)

Weaknesses

Data unavailable.

Opportunities

Data unavailable.

Threats

Data unavailable.

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Anuh Pharma Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.